![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Tasmanian Alkaloids Pty Ltd Westbury Au, based in Australia, is a pharmaceutical company that stands out with its certifications from FDA.
One of their significant offerings is Buprenorphine, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 1998-037 - Rev 03
This Chemical Type CEP, issued on July 22, 2016, remains in force until October 11, 2018, ensuring its reliability within the pharmaceutical industry.
Substance Number 1180 associated with this CEP further emphasizes